Post-earnings recap
Reported
Thu, Mar 12, 2020
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
50%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Axovant Therapeutics reported a loss per share of $0.71, which did not meet any expectations as revenue figures were not disclosed. The stock fell by over 12% following the earnings report, reflecting investor concerns about the lack of guidance and the company's ongoing challenges in the market. The absence of revenue data also contributed to uncertainty about the company's financial health moving forward.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.71 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Management acknowledged the challenges ahead without providing specific forward-looking guidance. They emphasized their commitment to advancing clinical programs.
Management did not provide specific guidance for future performance.
The company is focusing on its ongoing clinical trials.